Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Verastem (VSTM), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Verastem is one of 843 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VSTM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for VSTM's full-year earnings has moved 7.52% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, VSTM has gained about 65.80% so far this year. Meanwhile, the Medical sector has returned an average of 4.91% on a year-to-date basis. This means that Verastem is outperforming the sector as a whole this year.
To break things down more, VSTM belongs to the Medical - Biomedical and Genetics industry, a group that includes 341 individual companies and currently sits at #71 in the Zacks Industry Rank. This group has lost an average of 12.63% so far this year, so VSTM is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to VSTM as it looks to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Verastem, Inc. (VSTM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
